<div class="section">
<a class="named-anchor" id="ab-doi170042-1">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e237">Question</h5>
<p id="d4492539e239">What is the extent of potential financial conflicts of interest
among physicians who
author dermatology clinical practice guidelines?
</p>
</div><div class="section">
<a class="named-anchor" id="ab-doi170042-2">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e242">Findings</h5>
<p id="d4492539e244">In this cross-sectional, descriptive study of 49 authors of guidelines
published between
2013 and 2016, 40 received industry payments. Fifty-one percent received more than
$10 000, 37% received more than $50 000, and 24% received more than $100 000. Of the
40 authors receiving payments, 22 (55%) did not accurately disclose industry relationships
received between the initial literature search and guideline publication.
</p>
</div><div class="section">
<a class="named-anchor" id="ab-doi170042-3">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e247">Meaning</h5>
<p id="d4492539e249">These findings raise concern about potential financial conflicts
of interest in the
dermatology guideline development process.
</p>
</div><div class="section">
<a class="named-anchor" id="ab-doi170042-4">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e253">Importance</h5>
<p id="d4492539e255">It is well documented that financial conflicts of interest influence
medical research
and clinical practice. Prior to the Open Payments provisions of the Affordable Care
Act, financial ties became apparent only through self-disclosure. The nature of financial
interests has not been studied among physicians who develop dermatology clinical practice
guidelines.
</p>
</div><div class="section">
<a class="named-anchor" id="ab-doi170042-5">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e258">Objective</h5>
<p id="d4492539e260">To evaluate payments received by physicians who author dermatology
clinical practice
guidelines, compare disclosure statements for accuracy, determine whether pharmaceutical
companies from which the authors received payments manufactured products related to
the guidelines, and examine the extent to which the American Academy of Dermatology
enforced their Administrative Regulations for guideline development.
</p>
</div><div class="section">
<a class="named-anchor" id="ab-doi170042-6">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e263">Design, Setting, and Participants</h5>
<p id="d4492539e265">Three American Academy of Dermatology guidelines published from
2013 to 2016 were
retrieved. Double data extraction was used to record financial payments received by
49 guideline authors using the Open Payments database. Payments received by the authors
from the date of the initial literature search to the date of publication were used
to evaluate disclosure statement accuracy, detail the companies providing payments,
and evaluate Administrative Regulations enforcement. This study is applicable to clinical
practice guideline panels drafting recommendations, physicians using clinical practice
guidelines to inform patient care, and those establishing policies for guideline development.
</p>
</div><div class="section">
<a class="named-anchor" id="ab-doi170042-7">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e268">Main Outcomes and Measures</h5>
<p id="d4492539e270">Our main outcomes are the monetary values and types of payments
received by physicians
who author dermatology guidelines and the accuracy of disclosure statements. Data
were collected from the Open Payments database and analyzed descriptively.
</p>
</div><div class="section">
<a class="named-anchor" id="ab-doi170042-8">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e273">Results</h5>
<p id="d4492539e275">Of the 49 authors evaluated, 40 received at least 1 reported
industry payment, 31
accepted more than $1000, 25 accepted more than $10 000, and 18 accepted more than
$50 000. Financial payments amounted to a mean of $157 177 per author. The total reimbursement
among the 49 authors from 2013 to 2015 was $7 701 681. Of the 40 authors receiving
payments, 22 did not accurately disclose industry relationships. Authors received
payments from companies with products directly related to the guideline topic. Violations
to the Administrative Regulations were found.
</p>
</div><div class="section">
<a class="named-anchor" id="ab-doi170042-9">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d4492539e278">Conclusions and Relevance</h5>
<p id="d4492539e280">Dermatology clinical practice guideline authors received sizable
industry payments
and did not completely disclose these payments. The American Academy of Dermatology
policies may benefit from stricter enforcement or the adoption of new standards.
</p>
</div><p class="first" id="d4492539e283">This study uses data extraction from the
Open Payments database to evaluate the monetary
values and types of payments received by physician authors of dermatology guidelines
and the accuracy of conflict of interest disclosure statements.
</p>